Daniel Sullivan, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute


Oncology Tampa, FL

Hematologic Oncology

Professor, Oncologic Sciences, USF-Morsani

Dr. Sullivan is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sullivan's full profile

Already have an account?

Education & Training

  • University of Florida Affiliated HospitalsFellowship, Hematology, 1985 - 1988
  • University of Florida
    University of FloridaResidency, Internal Medicine, 1982 - 1985
  • University of LouisvilleMS, Biochemistry, 1982
  • University of Louisville School of Medicine
    University of Louisville School of MedicineClass of 1981
  • University of LouisvilleBA, Biology, Summa Cum Laude, 1974

Certifications & Licensure

  • KY State Medical License
    KY State Medical License 1988 - 2002
  • FL State Medical License
    FL State Medical License 1983 - 2022
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Invited Speaker 150th Anniversary of Tianjin Medical University, 2011
  • Visiting Professor Tianjin Medical University, Tianjin, China, 2010
  • Margaret Fonda Award in Biochemistry University of Louisville, 2005
  • Join now to see all

Clinical Trials

Publications & Presentations


Journal Articles

  • An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma  
    Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M, Eur J Haematol, 1/20/2015
  • Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRAC-mutant ovarian cancer  
    Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ, Szabo P, Youn A, Chen AP, Ji J, Allen DE, Lih C-J, Mehaffey MG, Wal..., Clin Cancer Res, 1/1/2015
  • Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer  
    Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A, Mol Cancer Ther, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Join now to see all


  • The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
    Daniel M Sullivan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Phase II Study of Sunitinib Malate (SM) in Subjects With Metastatic and/or Surgically Unresectable non-GIST Soft Tissue Sarcomas.
    Vigil CE, Chiappori AA, Williams CA, Shrager HH, Murray BL, Letson DG, Sullivan DM, Garrett CR, D'Amato GZ, Agresta SV, ASCO Annual Meeting Proceedings, 1/1/2008
  • Benefits (Survival) and Risks (30 Days Mortality) of Phase I Trials in Oncology.
    Djulbegovic B, Moreno C, Kumar A, Lush R, Munster PN, Daud AI, Garrett CR, Simon GR, Lancet JE, Sullivan DM, Phase I Program Physician and Nurses, ASCO Annual Meeting Proceedings, 1/1/2008
  • Join now to see all


  • "XP01 and Nuclear Export Inhibitors in Multiple Myeloma and AML" 
  • "Overcoming drug-resistance in multiple myeloma by XPO1 inhibitor combination therapy". 
    Barcelona, Spain - 1/18/2014
  • The Impact of Precision Oncology on Clinical Trials: Solving the Puzzle. 
    The Westin O'Hare, Chicago - 1/9/2014
  • Join now to see all


  • Efficacy of Topoisomerase I and II Inhibitors in Combination with Standard Chemotherapeutic Agents (Ara-C and Daunorubicin) in the Management of Acute Myeloid Leukemia... 
    Saba HI, Sullivan DM, Loughran Jr TP, Moscinski LC, Sullivan PA, Morelli GA
  • "Fractionation, kinetic properties, and inhibition by L-methionine analogs of rat liver and kidney methionine adenosyltransferase isozymes" 
    Sullivan DM, M.S. Thesis, University of Louisville

Press Mentions

  • Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA Approval
    Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA ApprovalJuly 26, 2019 00:41
  • ORIEN Uses Big Data to Improve Care for High-Risk Patients
    ORIEN Uses Big Data to Improve Care for High-Risk PatientsJune 04, 2017 10:23

Hospital Affiliations